IDXX vs. IQV, MCO, NVST, ZTS, BSX, SYK, MDT, BDX, EW, and RMD
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include IQVIA (IQV), Moody's (MCO), Envista (NVST), Zoetis (ZTS), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and ResMed (RMD).
IDEXX Laboratories vs. Its Competitors
IDEXX Laboratories (NASDAQ:IDXX) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.
IDEXX Laboratories has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
IQVIA has higher revenue and earnings than IDEXX Laboratories. IQVIA is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
IDEXX Laboratories has a net margin of 22.76% compared to IQVIA's net margin of 8.61%. IDEXX Laboratories' return on equity of 57.35% beat IQVIA's return on equity.
In the previous week, IDEXX Laboratories had 10 more articles in the media than IQVIA. MarketBeat recorded 33 mentions for IDEXX Laboratories and 23 mentions for IQVIA. IDEXX Laboratories' average media sentiment score of 1.11 beat IQVIA's score of 0.96 indicating that IDEXX Laboratories is being referred to more favorably in the media.
87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 1.0% of IDEXX Laboratories shares are held by insiders. Comparatively, 1.6% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
IDEXX Laboratories presently has a consensus price target of $558.11, suggesting a potential upside of 5.02%. IQVIA has a consensus price target of $222.45, suggesting a potential upside of 38.98%. Given IQVIA's higher possible upside, analysts plainly believe IQVIA is more favorable than IDEXX Laboratories.
Summary
IDEXX Laboratories beats IQVIA on 10 of the 16 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
This page (NASDAQ:IDXX) was last updated on 7/15/2025 by MarketBeat.com Staff
Free IDXX Stock Alerts